NanoSight Ltd is a company that designs and manufactures instruments for the scientific analysis of nanoparticles that are between approximately ten nanometers and one micron in diameter. The company was founded in 2003 by Bob Carr and John Knowles to further develop a technique Bob Carr had invented to visualize nanoparticles suspended in liquid. The company has since developed the technique of Nanoparticle Tracking Analysis , and they produce a series of instruments to count, size and visualize nanoparticles in liquid suspension using this patented technology.The company’s current headquarters is in Amesbury, Wiltshire, UK . NanoSight has 25 employees in the UK and has received several awards and recognitions. More than 450 instruments had been sold as of 2012. The technology has been cited in over 1300 scientific publications, presentations and reports.NanoSight was acquired by Malvern Instruments on the 30th September 2013. Wikipedia.
Methods in Molecular Biology | Year: 2012
Nanoparticle Tracking Analysis (NTA) provides direct and real time visualization, sizing, and counting of particulate materials between 10 nm and 1 μm in liquid suspension. The technique works on a particle-by-particle basis, relating the degree of movement under Brownian motion to the sphere equivalent hydrodynamic diameter particle size, allowing high resolution particle size distributions to be obtained within minutes. Here we describe application of NTA to the analysis of 100 nm polystyrene nanospheres in liquid suspension. The technique can be adapted for use with nearly all particulate materials with sizes between 10 nm and 1 μm. © 2012 Springer Science+Business Media, LLC.
Materials Today | Year: 2011
Nanoscale materials including nanotubes, nanowires, ceramics, quantum dots etc. can be produced from a huge variety of substances. Responsible development of new materials requires that risks to health and the environment associated with the development, production, use and disposal of these materials are fully addressed. Characterization of particles at the nanoscale thus becomes extremely important and new tools are being made available including the nanoparticle characterization systems from NanoSight and their technology, Nanoparticle Tracking Analysis. © 2011 Elsevier Ltd.
Agency: Cordis | Branch: FP7 | Program: CP-TP | Phase: NMP-2010-1.2-1 | Award Amount: 4.21M | Year: 2011
In-Sight is a SME-driven project on the in-line characterisation of nanoparticles during nanomaterial manufacturing. This in-line characterisation is the ultimate goal. Within the time-span of the project (3 years) it is our objective to show that a combination of analytical techniques that are capable of real time measurements will provide valuable information for the nanoparticle user. It is our objective to enable monitoring real-time (unexpected) changes in particle count and dimensions during particle processing. The outcome of the project will contribute to minimised batch failure, improved yield, troubleshooting scale-up. In addition, the in-line measurements will enable quality by design throughout development of new products. Finally the result of the project will be reflected in a reduction of development time, as well as easy scale-up from the lab to manufacturing.
NanoSight | Date: 2012-08-06
The present invention provides a method of analysing a sample comprising sub-micron particles, comprising determining first information about the size of particles and number of particles in the sample by nanoparticle tracking analysis; determining second information about average particle size of particles in the sample by dynamic light scattering; determining from the first information third information representing the theoretical effect of the detected particles on results obtainable by dynamic light scattering; and adjusting the second information using the third information to produce fourth information representing adjusted information on average particle size.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP-2009-4.0-3 | Award Amount: 16.52M | Year: 2010
NAMDIATREAM will develop a cutting edge nanotechnology-based toolkit for multi-modal detection of biomarkers of most common cancer types and cancer metastases, permitting identification of cells indicative of early disease onset in a high-specificity and throughput format in clinical, laboratory and point-of-care devices. The project is built on the innovative concepts of super-sensitive and highly specific lab-on-a-bead, lab-on-a-chip and lab-on-a-wire nano-devices utilizing photoluminescent, plasmonic, magnetic and non-linear optical properties of nanomaterials. This offers groundbreaking advantages over present technologies in terms of stability, sensitivity, time of analysis, probe multiplexing, assay miniaturisation and reproducibility. The ETP in Nanomedicine documents point out that nanotechnology has yet to deliver practical solutions for the patients and clinicians in their struggle against common, socially and economically important diseases such as cancer. Over 3.2M new cases and 1.7M cancer-related deaths are registered in Europe every year, largely because diagnostic methods have an insufficient level of sensitivity, limiting their potential for early disease identification. We will deliver Photoluminescent nanoparticle-based reagents and diagnostic chips for high throughput early diagnosis of cancer and treatment efficiency assessment Nanocrystals enabling plasmon-optical and nonlinear optical monitoring of molecular receptors within body fluids or on the surface of cancer cell Multi-Parameter screening of cancer biomarkers in diagnostic material implementing segmented magnetic nanowires Validation of nano-tools for early diagnosis and highly improved specificity in cancer research. OECD-compliant nanomaterials with improved stability, signal strength and biocompatibility Direct lead users of the results will be the diagnostic and medical imaging device companies involved in the consortium, clinical and academic partners